Vir Biotechnology, Inc. · NASDAQ:VIR
Vir Biotechnology — 20th Annual Needham Healthcare Conference 2021
19 slides from Vir Biotechnology's conference presentation, Apr 13, 2021
Slide 1: A World Without Infectious Disease
Vir Biotechnology, Inc. A WORLD WITHOUT INFECTIOUS DISEASE 20th Annual Needham Healthcare Conference April 13, 2021 Exhibit 99.1
Slide 2: Legal disclaimers: Forward-Looking Statements
Legal disclaimers © 2021 Vir Biotechnology, Inc. Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the expected success, cost, and tim
Slide 3: Taking on the most serious infectious diseases
© 2021 Vir Biotechnology, Inc. Taking on the most serious infectious diseases Clinically validated product candidates Applying learnings to broad ID pipeline Potential significant near-term value drivers
Slide 4: Clinically validated antibodies
mAB114*: approved for therapy; as effective as three-antibody cocktail from Regeneron Clinically validated antibodies © 2021 Vir Biotechnology, Inc. Ebola VIR-7831: 85% reduction in hospitalization or death; covers all known variants** COVID-19 VIR-3434: mean 1.3 log10 drop in HBsAg after single 6 m
Slide 5: Antibody engineering technologies
Antibody engineering technologies © 2021 Vir Biotechnology, Inc. XX2 vaccinal mutation LS mutation VIR-7831 VIR-3434 VIR-7832 VIR-2482 VIR-7832 VIR-3434 Licensed from Rockefeller University Increases potency Induces T cell protection Licensed from Xencor Extends half-life Increases tissue concentrat
Slide 6: Antibodies in R&D
Antibodies in R&D Based on preclinical data © 2021 Vir Biotechnology, Inc. RSV/MPV Malaria Other diseases Pan-coronavirus HIV MRSA Broad strain coverage Single antibody covers two related respiratory pathogens Blocks infection Potential for long-lasting prophylaxis C. Diff Dengue Let’s be ready for
Slide 7: Additional technology platforms
Additional technology platforms © 2021 Vir Biotechnology, Inc. siRNA Rights to Alnylam siRNA technology for a certain number of infectious diseases Includes ESC+ modification to reduce off-target activity and potentially increase safety CMV Vaccines (T cell) Systematic CRISPR screening Cellular targ
Slide 8: Vir clinical development pipeline
Disease Area Product Candidate Treatment/ Prophylaxis Pre-clinical Phase 1 Phase 2 Phase 3 Filed Collaborator COVID-19 VIR-7831 Treatment* VIR-7831 + bamlanivimab Treatment VIR-7831 Prophylaxis VIR-7832 Treatment HBV VIR-2218 Treatment VIR-2218 + PEG-IFN-⍺ Treatment VIR-3434 Treatment VIR-2218 + VIR
Slide 9: COVID-19
Vir Biotechnology, Inc. COVID-19
Slide 10: VIR-7831: Potential best-in-class efficacy and variant coverage
VIR-7831: Potential best-in-class efficacy and variant coverage * Sarbecoviruses. 1. Pinto D, et al. Nature. 2020;583:290–5; 2. Vir Biotechnology, Press release, 18 May 2020 (accessed November 13, 2020); 3. Hope, IAS 2019- HIV & HBV Cure Forum, Mexico City 4. VIR-7831 incorporates Xencor’s Xtend tec
Slide 11: VIR-7831 covers known variants in circulation
VIR-7831 covers known variants in circulation SA, BR mutant and other E484K + UK and other N501Y mutant + Scottish mutant + Mink mutant + Columbus and California mutant As of March 26, 2021, GISAID* Month & Year * GISAID (human spike protein seqs; <10% Xs; >1018 aa (80% full length) © 2021 Vir Biote
Slide 12: Potential next-generation antibodies
Potential next-generation antibodies © 2021 Vir Biotechnology, Inc. RBM Antibodies VIR-7832 Two leading candidates Highly potent in preclinical studies Cover all known variants in circulation Same epitope as VIR-7831 Enhanced for additional potency and induction of T cell protection with XX2 alterat
Slide 13: Hepatitis B (HBV)
Vir Biotechnology, Inc. Hepatitis B (HBV)
Slide 14: Broad HBV functional cure portfolio
Broad HBV functional cure portfolio © 2021 Vir Biotechnology, Inc. VIR-2218 Potential Best-In-Class siRNA as “backbone” of therapy Substantial, Durable, and Dose Dependent Reduction of HBsAg through 36 weeks Ongoing / Planned Combination Trials Placebo, n=8 20 mg, n=3 50 mg, n=9 100 mg, n=6 200 mg,
Slide 15: Attractive properties of VIR-3434
5,000-fold more potent than HBIG in in vitro neutralization assays Attractive properties of Vir-3434 © 2021 Vir Biotechnology, Inc. Potent Alteration in Fc shown to increase potency and induce protective T cell responses in animal models XX2 Positive safety data in healthy volunteers up to 3,000 mg
Slide 16: VIR-3434 Phase 1 clinical data
© 2021 Vir Biotechnology, Inc. VIR-3434 Phase 1 clinical data First blinded cohort of eight patients Two received placebo Six received a single 6 mg dose of VIR-3434 Six of eight patients achieved a mean reduction of 1.3 log10 IU/mL HBsAg by day eight, the day when nadir was achieved in most patient
Slide 17: Four abstracts accepted for EASL 2021
A Phase 1 study evaluating the neutralizing, vaccinal monoclonal antibody VIR-3434 in participants with chronic hepatitis B virus infection Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results Prelim
Slide 18: GSK collaboration 2.0
GSK collaboration 2.0 Expansion of original coronavirus collaboration to include: mAbs for influenza treatment and prevention (including an option on VIR-2482) Up to 3 mAbs for non-influenza infectious disease targets Functional genomics for respiratory targets $345m in upfront and equity investment
Slide 19: 2021 anticipated catalysts
© 2021 Vir Biotechnology, Inc. 2021 anticipated catalysts VIR-7831 (mAb) EUA (Early Treatment, COMET-ICE, IV) Authoriza-tion TBD VIR-7831 (mAb) Phase 3 (Early Treatment, COMET-TAIL, IM) Start 2Q VIR-7831 (mAb) Phase 3 (Prophylaxis, COMET-STAR, IM) Start 2Q VIR-7832 (mAb) Phase 1b/2a (Early Treatment
Vir Biotechnology — 20th Annual Needham Healthcare Conference 2021 on 6ix